Online citations, reference lists, and bibliographies.
← Back to Search

Pharmacokinetics And In Vivo Drug Release Rates In Liposomal Nanocarrier Development.

D. Drummond, C. Noble, M. Hayes, J. Park, D. Kirpotin
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Liposomes represent a widely varied and malleable class of drug carriers generally characterized by the presence of one or more amphiphile bilayers enclosing an interior aqueous space. Thus, the pharmacological profile of a particular liposomal drug formulation is a function not only of the properties of the encapsulated drug, but to a significant extent of the pharmacokinetics, biodistribution, and drug release rates of the individual carrier. Various physicochemical properties of the liposomal carriers, the drug encapsulation and retention strategies utilized, and the properties of the drugs chosen for encapsulation, all play an important role in determining the effectiveness of a particular liposomal drug. These properties should be carefully tailored to the specific drug, and to the application for which the therapeutic is being designed. Liposomal carriers are also amenable to additional modifications, including the conjugation of targeting ligands or environment-sensitive triggers for increasing the bioavailability of the drug specifically at the site of disease. This review describes the rationale for selecting optimal strategies of liposomal drug formulations with respect to drug encapsulation, retention, and release, and how these strategies can be applied to maximize therapeutic benefit in vivo.
This paper references
10.1016/S0169-409X(01)00204-6
Thermosensitive polymer-modified liposomes.
K. Kono (2001)
10.1073/PNAS.84.21.7413
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
P. Felgner (1987)
10.1016/0005-2736(91)90201-I
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
10.1126/science.1130651
A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs
Ian Cheong (2006)
10.1002/IJC.2910620215
Pharmacokinetics and anti‐tumor activity of vincristine encapsulated in sterically stabilized liposomes
T. Allen (1995)
Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy.
M. Schmitt‐Sody (2003)
10.1080/08982100600848702
Lipophilic Drug Transfer Between Liposomal and Biological Membranes: What Does It Mean for Parenteral and Oral Drug Delivery?
A. Fahr (2006)
10.1016/j.jconrel.2005.10.011
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention.
I. V. Zhigaltsev (2006)
10.2174/1381612053382133
The design of cationic lipids for gene delivery.
B. Martin (2005)
10.1002/(SICI)1097-0215(19970328)71:1<103::AID-IJC17>3.0.CO;2-J
Activity of paclitaxel liposome formulations against human ovarian tumor xenografts
A. Sharma (1997)
10.2165/00003088-200342050-00002
Pharmacokinetics of Pegylated Liposomal Doxorubicin
A. Gabizon (2003)
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
F. Pastorino (2003)
Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy.
G R Martin (1994)
10.1016/J.JCONREL.2006.01.005
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.
T. Ishida (2006)
10.1016/J.JCONREL.2005.08.023
Liposomalization of SN-38 as active metabolite of CPT-11.
Y. Sadzuka (2005)
10.1016/S0169-409X(99)00035-6
Cytosolic drug delivery using pH- and light-sensitive liposomes.
Gerasimov (1999)
10.1038/NBT0297-167
Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery
Y. Liu (1997)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
D. Drummond (1999)
10.1158/1078-0432.CCR-04-2517
Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates
T. Allen (2005)
10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
10.1016/S0005-2736(98)00077-7
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
M. Webb (1998)
10.1016/S0169-409X(97)00133-6
Receptor versus non-receptor mediated clearance of liposomes.
Kamps (1998)
10.1016/J.JCONREL.2006.05.019
Copper-topotecan complexation mediates drug accumulation into liposomes.
Amandeep S Taggar (2006)
10.1016/0006-2952(83)90483-5
The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice.
C. Kirby (1983)
10.1023/A:1016096910822
Targeted Delivery of Doxorubicin via Sterically Stabilized Immunoliposomes: Pharmacokinetics and Biodistribution in Tumor-bearing Mice
N. Emanuel (2004)
10.1016/S0169-409X(01)00233-2
The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.
D. Needham (2001)
10.1016/J.YGYNO.2004.09.046
Role of pegylated liposomal doxorubicin in ovarian cancer.
J. Thigpen (2005)
10.1200/JCO.2005.03.8331
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
10.1016/0005-2736(81)90464-8
A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles.
T. Allen (1981)
10.1021/BC980047Y
Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome.
S. C. Davis (1998)
Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
M. Sugano (2000)
10.1097/00001813-200208000-00005
Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation
J. Liu (2002)
Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously.
S. Dow (1999)
10.1016/0009-3084(90)90131-A
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.
T. Madden (1990)
10.1158/1078-0432.CCR-05-0343
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Kimberley M Laginha (2005)
10.1200/JCO.2005.04.937
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
W. Gradishar (2005)
10.1023/A:1018994111594
Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes
Amarnath Sharma (2004)
10.1016/0005-2736(72)90354-9
Permeability properties of phospholipid membranes: effect of cholesterol and temperature.
D. Papahadjopoulos (1972)
10.1016/S0005-2736(99)00234-5
In vitro characterization of a novel polymeric-based pH-sensitive liposome system.
M. Zignani (2000)
10.1016/0169-409X(95)00029-7
Pharmacokinetics of long-circulating liposomes
T. Allen (1995)
10.1007/s11095-006-9111-5
Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation
E. Ramsay (2006)
10.2165/00002018-200124120-00004
A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form
D. Waterhouse (2001)
10.1073/PNAS.83.8.2699
Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo.
D. Aragnol (1986)
10.1053/J.SEMINONCOL.2004.08.006
Cardiac safety of liposomal anthracyclines.
M. Ewer (2004)
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
G. Colbern (1998)
10.1007/s10555-007-9046-2
Human reduced folate carrier: translation of basic biology to cancer etiology and therapy
L. Matherly (2007)
Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
T. Sakakibara (1996)
10.1006/ABIO.1995.0001
Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.
L. Mayer (1995)
10.1016/S0005-2736(02)00602-8
Rapid release of liposomal contents upon photoinitiated destabilization with UV exposure.
T. Spratt (2003)
10.1016/S0163-7827(03)00033-X
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties.
S. Moghimi (2003)
10.1016/0022-1759(89)90298-6
Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates.
J. A. Peeters (1989)
10.1158/0008-5472.CAN-05-3535
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
C. Noble (2006)
10.1089/HUM.1997.8.4-393
Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice.
S. Parker (1997)
Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
E. Mayhew (1979)
10.1016/S0006-3495(90)82444-9
Elastic deformation and failure of lipid bilayer membranes containing cholesterol.
D. Needham (1990)
10.1016/J.PLIPRES.2004.12.001
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
T. Andresen (2005)
10.1016/S0005-2736(97)00129-6
Enhancement of the in vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine liposomes: importance of liposomal aggregation versus complement opsonization.
P. Ahl (1997)
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
G. Kong (2000)
10.1016/S0005-2736(02)00661-2
Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity.
G. Charrois (2003)
10.1016/S0169-409X(01)00232-0
Phototriggering of liposomal drug delivery systems.
P. Shum (2001)
10.1016/J.EJPB.2004.06.009
Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.
J. Zhang (2005)
10.1038/sj.bjc.6603345
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
S. White (2006)
10.1517/14728222.8.4.335
Development of ligand-targeted liposomes for cancer therapy
C. Noble (2004)
10.3816/CLM.2007.N.001
Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
R. Manochakian (2007)
10.1158/1078-0432.CCR-0929-3
Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies
C. Verschraegen (2004)
Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.
E. Forssen (1996)
10.1016/S0076-6879(04)87008-3
Sterically stabilized ph-sensitive liposomes.
V. Slepushkin (2004)
10.1074/jbc.272.4.2382
Sterically Stabilized pH-sensitive Liposomes
V. Slepushkin (1997)
10.1016/J.JCONREL.2007.02.010
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Xinyu Wang (2007)
10.1002/JPS.20332
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
S. Semple (2005)
10.1002/ijc.20083
Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature
S. Strieth (2004)
10.1016/S0169-5002(01)00278-1
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
E. Kim (2001)
10.1016/J.JCONREL.2004.02.017
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
S. Abraham (2004)
10.1016/S0168-3659(01)00343-1
The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
D. Bom (2001)
10.1016/J.BBAMEM.2006.01.009
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
M. J. W. Johnston (2006)
10.1152/AJPRENAL.00316.2002
Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys.
U. Lund (2003)
10.1158/0008-5472.CAN-05-1093
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
C. Mamot (2005)
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
L. Xu (2002)
10.1002/jgm.634
Low‐pH‐sensitive poly(ethylene glycol) (PEG)‐stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery
Weijun Li (2005)
10.1016/j.jneumeth.2005.12.027
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: Implications for local drug delivery
Ryuta Saito (2006)
10.1073/pnas.0601455103
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging
J. Yang (2006)
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
F. Pastorino (2003)
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.
P. Laverman (2000)
10.1177/096032719901800103
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
10.1016/0005-2736(91)90167-7
Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo.
A. Chonn (1991)
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
D. E. Lopes de Menezes (1998)
Membrane cholesterol and phospholipid in consecutive concentric sections of human lenses.
L. Li (1985)
10.1016/0005-2736(89)90078-3
Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues.
T. Allen (1989)
10.1152/AJPHEART.1996.270.1.H324
Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory.
M. Swartz (1996)
10.1158/1535-7163.MCT-06-0118
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
L. Mayer (2006)
10.1016/S0168-3659(03)00271-2
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel.
M. Immordino (2003)
10.1016/S0168-3659(99)00198-4
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
M. Ceruti (2000)
10.1016/J.BBAMEM.2006.12.013
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.
N. Dos Santos (2007)
10.1016/S0167-4889(02)00256-2
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
U. Nielsen (2002)
10.1021/BI00205A013
Interaction of cholesterol with sphingomyelin in monolayers and vesicles.
R. Bittman (1994)
10.1177/0091270006288953
Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients
A. Bedikian (2006)
10.1124/JPET.103.053413
Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity
G. Charrois (2003)
10.1016/0005-2736(92)90034-J
Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo.
Y. S. Park (1992)
10.1016/S0005-2736(00)00359-X
Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance.
T. Peleg-Shulman (2001)
10.1208/ps050432
Pharmacokinetics of paclitaxel-containing liposomes in rats
G. Fetterly (2008)
10.1200/JCO.2005.02.028
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
G. Dark (2005)
10.1146/ANNUREV.BIOENG.8.061505.095735
Recent approaches to intracellular delivery of drugs and DNA and organelle targeting.
V. Torchilin (2006)
10.1016/S0163-7827(00)00011-4
Current status of pH-sensitive liposomes in drug delivery.
D. Drummond (2000)
10.1021/LA0631668
Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.
A. Schroeder (2007)
10.1096/fj.02-0487fje
Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery
P. Sonveaux (2002)
10.1016/S0163-7827(03)00032-8
Ligand-targeted liposomal anticancer drugs.
P. Sapra (2003)
10.1016/S0005-2736(98)00166-7
Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients.
D. Fenske (1998)
10.1007/s002800050855
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
M. S. Newman (1999)
10.1093/JNCI/81.19.1484
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.
A. Gabizon (1989)
10.1007/s10555-007-9044-4
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
J. Zhang (2007)
10.1016/0005-2760(81)90268-X
Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition.
J. Damen (1981)
10.1016/S0005-2736(02)00345-0
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
N. Dos Santos (2002)
10.2174/156720105774370294
The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
E. Ramsay (2005)
10.1021/AR9703241
Chemical approaches to triggerable lipid vesicles for drug and gene delivery.
Xin Guo (2003)
10.1038/nbt1122
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
David V Morrissey (2005)
Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.
S. Huang (1994)
10.1016/s0021-9258(18)68843-x
pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide.
R. Parente (1988)
10.1021/BI001038R
Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line.
S. Lobert (2000)
10.1007/BF00689191
A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo
S. A. Longman (2004)
10.1007/s00280-006-0235-4
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer
T. Dragovich (2006)
10.1016/J.PUPT.2007.04.002
Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes.
L. Zhang (2008)
10.1016/J.JPBA.2004.09.053
A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).
S. Khan (2005)
10.1200/JCO.2005.00.802
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
C. Lu (2005)
10.1016/0005-2736(91)90246-5
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo.
T. Allen (1991)
10.1016/0009-3084(94)02398-O
Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids.
D. C. Drummond (1995)
10.1152/AJPHEART.1997.273.1.H387
Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice.
J. W. Mclean (1997)
10.1007/s11095-006-9180-5
Lipid-based Nanoparticles for Nucleic Acid Delivery
Weijun Li (2006)
10.1200/JCO.1998.16.2.683
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
S. Stewart (1998)
10.1023/A:1015908831507
Efficiency of Cytoplasmic Delivery by pH-Sensitive Liposomes to Cells in Culture
Chun-Jung Chu (2004)
10.1016/S0005-2736(99)00209-6
A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.
D. Stuart (2000)
10.1016/j.brainres.2004.12.007
Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating
J. MacKay (2005)
10.1158/1078-0432.CCR-04-0221
Liposomal Irinotecan
C. Messerer (2004)
Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
A. Cabanes (1998)
Liver pathology accompanying chronic liposome administration in mouse.
T. Allen (1985)
Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor.
C. van Bree (1996)
10.1562/0031-8655(2000)072<0057:AUODIP>2.0.CO;2
Active Uptake of Drugs into Photosensitive Liposomes and Rapid Release on UV Photolysis¶
R. Bisby (2000)
10.1093/ANNONC/MDL477
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
D. Lorusso (2007)
10.1016/0005-2736(90)90018-J
Liposomes with entrapped doxorubicin exhibit extended blood residence times.
M. Bally (1990)
10.1053/J.SEMINONCOL.2004.08.001
Advantages of liposomal delivery systems for anthracyclines.
T. Allen (2004)
10.1021/BC025625W
Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization.
J. S. Choi (2003)
Liposomes: From Physics to Applications
D. Lasič (1993)
10.1016/S0169-409X(02)00179-5
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities.
G. Saito (2003)
10.1080/10611860400015936
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
P. Lockman (2004)
Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
B. Mui (2001)
10.1016/S0005-2736(98)00204-1
Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients.
E. Maurer-Spurej (1999)
10.1016/S0168-3659(02)00462-5
Accelerated clearance of PEGylated liposomes in rats after repeated injections.
T. Ishida (2003)
10.1016/j.jconrel.2005.09.053
Barriers to carrier mediated drug and gene delivery to brain tumors.
Grace H Huynh (2006)
10.1002/JPS.1063
Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes.
R. Campbell (2001)
10.1016/S0005-2736(98)00125-4
Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study.
N. Maurer (1998)
10.1093/ANNONC/MDL484
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
E. Andreopoulou (2007)
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
L. Mayer (1989)
Physicochemical and pharmacokinetic characteristics of cationic liposomes.
W. Yeeprae (2006)
10.1007/BF00689270
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes
M. Bally (2004)
10.1042/BJ3560747
Reducible cationic lipids for gene transfer.
B. Wetzer (2001)
10.1016/J.JCONREL.2005.01.010
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
I. V. Zhigaltsev (2005)
10.1016/0005-2736(80)90225-4
The bilayer stabilizing role of sphingomyelin in the presence of cholesterol: a 31P NMR study.
P. Cullis (1980)
10.1016/0005-2736(85)90497-3
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential.
L. Mayer (1985)
10.1016/J.INTIMP.2007.04.002
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Kaley D. Wilson (2007)
10.1016/J.JCONREL.2006.09.018
Design, synthesis and application of vinyl ether compounds for gene and drug delivery.
J. Van den Bossche (2006)
10.1158/1078-0432.CCR-05-1365
Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model
Robert D Arnold (2005)
10.1200/JCO.1998.16.7.2445
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
D. Northfelt (1998)
10.2174/187152006778699121
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.
T. Allen (2006)
10.1002/IJC.2910510221
Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid
E. Mayhew (1992)
10.1016/S0005-2736(97)00056-4
Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
J. A. Harding (1997)
10.1016/0005-2736(93)90115-G
Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection.
T. Allen (1993)
10.1158/0008-5472.CAN-03-3631
Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging
Ryuta Saito (2004)
10.1007/s00280-003-0719-4
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
W. Zamboni (2003)
10.1016/S0005-2736(98)00256-9
Elastase activated liposomal delivery to nucleated cells.
C. C. Pak (1999)
Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
H. Lim (1997)
10.1016/J.JMB.2007.05.011
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
Yu Zhou (2007)
Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
M. J. Parr (1997)
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
R. Pérez-Soler (1997)
10.1124/JPET.103.064725
Pharmacokinetics, Safety, and Efficacy of a Liposome Encapsulated Thymidylate Synthase Inhibitor, OSI-7904L [(S)-2-[5-[(1,2-Dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric Acid] in Mice
J. Desjardins (2004)
10.1128/AAC.42.1.45
Antibacterial Efficacy against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation
M. Webb (1998)
10.1016/J.AB.2004.09.046
Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study.
W. Guo (2005)
Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
P. Sapra (2002)
10.1016/S0168-3659(03)00232-3
Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids.
Junhwa Shin (2003)
10.1038/sj.gt.3302699
Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery
M. E. Hayes (2006)
10.2165/00003088-200645120-00002
Pharmacology of Drugs Formulated with DepoFoam™
M. Angst (2006)
10.1023/A:1018907715905
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs
A. Gabizon (2004)
10.1016/0005-2736(92)90194-Q
Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes.
M. Woodle (1992)
10.1016/0005-2736(95)00214-6
Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients.
S. Clerc (1995)
10.1016/J.BBAMEM.2007.01.019
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin.
M. J. W. Johnston (2007)
10.1016/S0169-409X(96)00476-0
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
A. Gabizon (1997)
10.1038/bjc.1995.430
Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
M. Webb (1995)
10.1021/BI00499A014
Interaction of cholesterol with various glycerophospholipids and sphingomyelin.
M. Sankaram (1990)
10.1016/S0006-3495(03)74963-7
Hydrogen-bonding propensities of sphingomyelin in solution and in a bilayer assembly: a molecular dynamics study.
E. Mombelli (2003)
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
D. Emerson (2000)
10.1016/0014-5793(92)80947-F
Gelation of liposome interior A novel method for drug encapsulation
D. Lasic (1992)
10.3109/10611869608996830
Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.
A. Gabizon (1996)
10.1002/cncr.21662
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma
R. Rifkin (2006)
10.1016/0005-2760(93)90132-S
The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade.
M. J. Parr (1993)
10.1016/J.JCONREL.2005.04.003
Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
T. Ishida (2005)
10.1158/1078-0432.CCR-04-2291
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
A. Sparreboom (2005)
10.1089/HUM.1996.7.12-1437
Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery.
C. Plank (1996)
10.1016/S0169-409X(01)00205-8
Enzyme-activated targeting of liposomes.
P. Meers (2001)
10.1002/JPS.2600660720
Liposomal entrapment of floxuridine.
S. Simmons (1977)
10.1080/09687860400010516
Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents
T. Chen (2004)
10.1016/0304-4165(88)90049-9
Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes.
G. Storm (1988)
10.1016/J.BBAMEM.2006.11.014
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
P. Tardi (2007)
Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
A. Pal (2005)
10.1016/J.IJPHARM.2003.10.015
Development and characterization of a novel liposome-based formulation of SN-38.
J. Zhang (2004)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1158/1078-0432.CCR-1131-03
In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading
S. Abraham (2004)
Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.
S. S. Williams (1993)
10.1016/0167-4889(88)90184-X
UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES
J.T.P. Derksen (1988)
10.1021/BC980002X
Liposome-anchored vascular endothelial growth factor aptamers.
M. Willis (1998)
10.1016/0169-409X(95)00030-B
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
A. Gabizon (1995)
10.1038/11710
Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity
Gitanjali Adlakha-Hutcheon (1999)
10.1007/s002800050409
In vivo antitumor activity of cis-bis-neodecanoato-trans- R,R-l,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes
A. Mori (2009)
10.1111/j.1749-6632.2000.tb07063.x
Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9‐Nitro‐20(S)‐Camptothecin in Patients with Advanced Malignancies in the Lungs
C. Verschraegen (2000)
10.1016/J.JCONREL.2006.08.017
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
T. Ishida (2006)
10.1016/B978-044482917-7/50014-4
CHAPTER 4.2 – Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes
L. Mayer (1998)
10.1085/JGP.106.1.67
The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons
M. Lande (1995)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Dayan Ad (1996)
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
J. Park (2002)
10.1016/S0169-409X(99)00041-1
The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.
Nagayasu (1999)
Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
P. Tardi (2000)
10.1158/1078-0432.CCR-04-2445
Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes
D. Drummond (2005)
10.1038/NBT0696-760
pH-sensitive, cationic liposomes: A new synthetic virus-like vector
V. Budker (1996)
10.1016/0005-2736(96)00003-X
Influence of dose on liposome clearance: critical role of blood proteins.
C. Oja (1996)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1016/J.BBAMEM.2004.03.006
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
G. Charrois (2004)
10.1016/S0169-409X(97)00128-2
Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo.
Cullis (1998)
10.1200/JCO.20.5.1222
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
D. Kehrer (2002)
10.1021/BI0019803
Interaction of cholesterol with sphingomyelin in mixed membranes containing phosphatidylcholine, studied by spin-label ESR and IR spectroscopies. A possible stabilization of gel-phase sphingolipid domains by cholesterol.
M. P. Veiga (2001)
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.
R. Campbell (2002)
10.1016/S0959-8049(01)00330-6
Phase III data on Caelyx in ovarian cancer.
F. Muggia (2001)
10.1016/S0959-8049(01)00171-X
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
H. Gelderblom (2001)
10.1016/0005-2736(90)90091-2
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
L. Mayer (1990)
10.1158/0008-5472.CAN-05-4007
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
D. Drummond (2006)
10.1152/AJPRENAL.2000.279.1.F84
Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin.
M. Ohlson (2000)
10.1074/JBC.M011553200
Extracellular Glycosaminoglycans Modify Cellular Trafficking of Lipoplexes and Polyplexes*
M. Ruponen (2001)
10.1007/s002800100371
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
J. M. Meerum Terwogt (2002)
10.1016/0014-4827(84)90711-0
Interaction of liposomes with Kupffer cells in vitro.
J. Dijkstra (1984)
10.1016/J.YMTHE.2005.09.014
Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
A. Judge (2006)
10.1002/cncr.21595
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
D. Thomas (2006)
Fate and behavior of liposomes in vivo: a review of controlling factors.
J. H. Senior (1987)
10.1615/CRITREVTHERDRUGCARRIERSYST.V17.I5.10
Drug targeting by surface cationization.
S. Blau (2000)
10.1016/S0006-3495(01)76203-0
Membrane properties of D-erythro-N-acyl sphingomyelins and their corresponding dihydro species.
M. Kuikka (2001)
10.1093/JNCI/DJH221
Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
C. Brignole (2004)
10.1016/s0021-9258(19)37026-7
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
A. Chonn (1992)
10.1124/JPET.104.078113
Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid
S. Semple (2005)
10.1038/sj.gt.3301365
Novel gene delivery systems: complexes of fusigenic polymer-modified liposomes and lipoplexes
K. Kono (2001)
10.1016/S0360-3016(96)00389-6
Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks.
M. H. Gaber (1996)
10.1200/JCO.1997.15.5.2111
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
E. Casper (1997)
10.1215/15228517-2006-001
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Ryuta Saito (2006)
10.1093/JNCI/90.4.300
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
J. Szebeni (1998)
10.1124/pr.56.2.6
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
G. Minotti (2004)
10.3109/08982109409037065
Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)
M. S. Newman (1994)
10.1016/J.BBAMEM.2005.02.001
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.
E. Ambegia (2005)
10.1080/089583701753403980
9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS
B. Gilbert (2002)
10.1152/AJPLUNG.1994.267.3.L223
Regulation of vascular endothelial barrier function.
H. Lum (1994)
10.1016/J.EJPS.2005.05.012
Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
A. Fahr (2005)
10.1016/0024-3205(82)90455-6
Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components.
J. Senior (1982)
10.1016/s0021-9258(19)70482-7
Introduction of liposome-encapsulated SV40 DNA into cells.
R. Fraley (1980)
10.1038/sj.gt.3300865
Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection
S. Li (1999)
10.1021/BI002791N
Cholesterol decreases the interfacial elasticity and detergent solubility of sphingomyelins.
X. Li (2001)
Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
R. Krishna (2001)
10.1158/1078-0432.CCR-03-0041
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
10.1007/s00280-005-0145-x
Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity
S. Shan (2005)
10.1016/0005-2736(93)90105-9
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
10.1093/JNCI/92.16.1295
A family of drug transporters: the multidrug resistance-associated proteins.
P. Borst (2000)
Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.
A. Gabizon (1990)
10.1529/BIOPHYSJ.104.048702
Structure and dynamics of sphingomyelin bilayer: insight gained through systematic comparison to phosphatidylcholine.
P. Niemelä (2004)
10.1016/0005-2736(73)90280-0
Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity.
D. Papahadjopoulos (1973)
Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
R. Zhou (2002)
10.1016/0014-5793(96)00521-2
Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol)
D. Kirpotin (1996)
10.1007/BF00686828
Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model
A. Mori (2004)
10.1093/JNCI/77.2.459
Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
A. Gabizon (1986)
10.1016/S0169-409X(01)00154-5
Liposomes to target the lymphatics by subcutaneous administration.
C. Oussoren (2001)
10.1007/s11095-005-5646-0
Targeting of the Antivascular Drug Combretastatin to Irradiated Tumors Results in Tumor Growth Delay
C. Pattillo (2005)
10.1021/BI00568A027
Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein.
J. Chobanian (1979)
10.1016/J.ADDR.2004.12.004
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity.
Jing-Shi Zhang (2005)
10.1038/nature04688
RNAi-mediated gene silencing in non-human primates
T. Zimmermann (2006)
10.1016/S0163-7827(02)00004-8
A lipid based depot (DepoFoam technology) for sustained release drug delivery.
S. Mantripragada (2002)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.3109/10611860009102218
Stabilized Plasmid–Lipid Particles: Pharmacokinetics and Plasmid Delivery to Distal Tumors following Intravenous Injection
M. Monck (2000)
10.1093/JNCI/DJK005
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
A. M. Ponce (2007)
10.1016/0005-2736(94)90038-8
Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes.
D. C. Litzinger (1994)
10.1021/BI950414I
Influence of cholesterol on the association of plasma proteins with liposomes.
S. Semple (1996)
10.1016/S0169-409X(99)00039-3
Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes.
Harashima (1999)
10.1002/mrm.20074
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery
B. Viglianti (2004)
10.1159/000093005
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)
10.1016/0005-2736(90)90102-T
Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerols.
D. Collins (1990)
10.1007/s00280-004-0825-y
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
K. Mross (2004)
10.1158/0008-5472.CAN-03-0576
Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts
C. Davies (2004)
Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
H. Lim (2000)
Conformational studies of sphingolipids by NMR spectroscopy
I. Dihydrosphingomyelin (2000)
10.1126/SCIENCE.7434025
pH-sensitive liposomes: possible clinical implications.
M. Yatvin (1980)
10.1016/0005-2736(94)90004-3
Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles.
M. J. Parr (1994)
10.1016/j.expneurol.2005.08.016
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain
Ryuta Saito (2005)
10.1016/0005-2736(95)00159-Z
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
D. Lasic (1995)
10.1016/S0005-2736(98)00129-1
Ultrastructural characterization of cationic liposome-DNA complexes showing enhanced stability in serum and high transfection activity in vivo.
B. Sternberg (1998)
10.1016/J.DRUP.2006.09.001
The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Y. Assaraf (2006)
10.1073/PNAS.90.3.893
Cyclic amphipathic peptide-DNA complexes mediate high-efficiency transfection of adherent mammalian cells.
J. Legendre (1993)
10.1016/0092-8674(79)90296-4
The introduction of poliovirus RNA into cells via lipid vesicles (liposomes)
T. Wilson (1979)
10.1016/J.ADDR.2003.10.039
Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules.
M. Yessine (2004)
10.1016/0304-3835(96)04380-7
Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia.
A. Sharma (1996)
10.1016/S0304-4157(97)00006-3
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles.
P. Cullis (1997)
10.1016/J.YMTHE.2004.10.013
Thiocholesterol-based lipids for ordered assembly of bioresponsive gene carriers.
Z. Huang (2005)
10.1016/s0005-2736(00)00229-7
Conformational studies of sphingolipids by NMR spectroscopy. II. Sphingomyelin.
C. Talbott (2000)



This paper is referenced by
10.1002/jps.23508
Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies.
S. J. Wallace (2013)
10.4155/tde.13.41
Innovative approaches for demonstration of bioequivalence: the US FDA perspective.
X. Zhang (2013)
10.1016/J.JTICE.2008.10.006
Magnolol encapsulated by different acyl chain length of liposomes on inhibiting proliferation of smooth muscle cells
C. Chen (2009)
10.1021/acsami.5b03204
Ratiometric Monitoring of Intracellular Drug Release by an Upconversion Drug Delivery Nanosystem.
K. Li (2015)
10.1039/C7TB00382J
Gadolinium-based nanoscale MRI contrast agents for tumor imaging.
Y. Cao (2017)
10.1158/1078-0432.CCR-10-2049
Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation Using PET
C. B. Rygh (2010)
10.2174/2210303103999131211110908
Liposomes as Triggerable Carrier for Intracellular Drug Delivery
N. Kumar (2014)
10.1016/j.jconrel.2012.04.041
Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound.
H. Grüll (2012)
EVOLUTION OF LIPOSOMAL CARRIERS INTENDED TO ANTICANCER DRUG DELIVERY: AN OVERVIEW
M. Estanqueiro (2014)
10.1126/scisignal.aat0229
Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway
Ozan Alkan (2018)
10.2147/IJN.S150512
Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
L. Zhang (2018)
10.3390/molecules200915893
Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma
L. Liguori (2015)
10.1016/j.jconrel.2010.07.117
Ultrasound triggered, image guided, local drug delivery.
R. Deckers (2010)
Photobiological properties of photoactive nanoparticles for the treatment of cancer
V. Reshetov (2012)
10.1002/smll.202000673
Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation.
X. Liu (2020)
10.1038/clpt.2012.12
Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents
W. Caron (2012)
10.1007/s11095-014-1458-4
Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
Kohsuke Shakushiro (2014)
10.2174/1389200216666150223152958
Advances and challenges in the use of nanoparticles to optimize PK/PD interactions of combined anti-cancer therapies.
Y. Liu (2014)
10.1016/j.ejpb.2019.09.002
Challenges and Strategies in Drug Delivery Systems for Treatment of Pulmonary Infections.
Duy-Khiet Ho (2019)
10.1208/s12249-011-9674-2
Synthesis of Monomethoxypolyethyleneglycol—Cholesteryl Ester and Effect of its Incorporation in Liposomes
V. Sant (2011)
10.1208/s12249-018-1182-1
Radiolabeling of Preformed Niosomes with [99mTc]: In Vitro Stability, Biodistribution, and In Vivo Performance
A. Almasi (2018)
10.1016/j.colsurfb.2017.01.014
Recent advances in compartmentalized synthetic architectures as drug carriers, cell mimics and artificial organelles.
M. J. York-Duran (2017)
10.1007/978-3-030-41333-0
A Handbook of Gene and Cell Therapy
Clévio Nóbrega (2020)
10.1039/c5nr04353k
A dual pH/thermal responsive nanocarrier for combined chemo-thermotherapy based on a copper-doxorubicin complex and gold nanorods.
Mingzhu Lei (2015)
10.1016/j.jconrel.2013.04.005
SPECT/CT imaging of temperature-sensitive liposomes for MR-image guided drug delivery with high intensity focused ultrasound.
M. de Smet (2013)
10.1227/NEU.0000000000000552
Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats.
S. Joshi (2015)
10.1002/jps.22573
Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes.
B. K. Aithal (2011)
10.1016/j.ijpharm.2016.11.002
Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects.
W. Badri (2016)
10.3109/02656736.2012.736670
Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia
R. Staruch (2012)
10.1039/c2cc32962j
Selective non-covalent triggered release from liposomes.
Adam J. Plaunt (2012)
10.1016/j.ejmech.2014.07.073
"Switch off/switch on" regulation of drug cytotoxicity by conjugation to a cell targeting peptide.
Y. Gilad (2014)
10.1016/j.jconrel.2014.05.043
Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes.
A. López-Noriega (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar